Procurement, isolation and cryopreservation of endometrial/menstrual cells

• US 20080241113A1
• Filed: 03/03/2008
• Published: 10/02/2008
• Est. Priority Date: 03/01/2007
• Status: Abandoned Application

• Current Assignee: Cryo-Cell International Incorporated
• Original Assignee: Cryo-Cell International Incorporated
• Inventors: Allickson, Julie G., Walton, Mercedes A.
• Application Number:
  US12/074,423
• Publication Number:
  US 20080241113A1
• Time in Patent Office: Days
• US Class Current: 424/93.7
• CPC Class Codes: A01N 1/02 Preservation of living parts
• CPC Class Codes: A01N 1/0221 Freeze-process protecting agents, i.e. substances protecting cells from effects of the physical process, e.g. cryoprotectants, osmolarity regulators like oncotic agents
• CPC Class Codes: A61K 2800/10 General cosmetic use
• CPC Class Codes: A61K 35/14 Blood; Artificial blood perfluorocarbons A61K31/02; umbilical cord blood A61K35/51; haemoglobin A61K38/42
• CPC Class Codes: A61K 35/48 Reproductive organs
• CPC Class Codes: A61K 8/983 Blood, e.g. plasma
• CPC Class Codes: A61P 1/02 Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 11/00 Drugs for disorders of the respiratory system
• CPC Class Codes: A61P 15/00 Drugs for genital or sexual disorders for disorders of sex hormones A61P5/24; Contraceptives
• CPC Class Codes: A61P 15/08 for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• CPC Class Codes: A61P 17/00 Drugs for dermatological disorders
• CPC Class Codes: A61P 17/02 for treating wounds, ulcers, burns, scars, keloids, or the like
• CPC Class Codes: A61P 17/10 Anti-acne agents
• CPC Class Codes: A61P 17/14 for baldness or alopecia
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 21/00 Drugs for disorders of the muscular or neuromuscular system
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 25/16 : Anti-Parkinson drugs
• CPC Class Codes: A61P 25/28 : for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 27/02 : Ophthalmic agents
• CPC Class Codes: A61P 29/00 : Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/10 : for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: A61P 35/02 : specific for leukemia
• CPC Class Codes: A61P 39/00 : General protective or antinoxious agents
• CPC Class Codes: A61P 43/00 : Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 5/00 : Drugs for disorders of the endocrine system
• CPC Class Codes: A61P 5/48 : of the pancreatic hormones
• CPC Class Codes: A61P 7/06 : Antianaemics
• CPC Class Codes: A61P 9/00 : Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/10 : for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• CPC Class Codes: A61Q 17/04 : Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
• CPC Class Codes: A61Q 19/00 : Preparations for care of the skin
• CPC Class Codes: A61Q 19/08 : Anti-ageing preparations
• CPC Class Codes: A61Q 5/00 : Preparations for care of the hair
• CPC Class Codes: C12N 5/0682 : Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells oocytes C12N5/0609
• CPC Class Codes: G01N 2333/705 : Assays involving receptors, cell surface antigens or cell surface determinants
• CPC Class Codes: G01N 33/5073 : Stem cells
• CPC Class Codes: G01N 33/689 : related to pregnancy or the gonads

Abstract

Compositions comprising menstrual stem cells (MSCs) and methods, processes, and system therefor are provided by the invention. MSCs are processed from menstrual flow collected during menses. MSCs may be cryopreserved, processed through various culturing and selection steps in preparation for cryopreservation, or processed for therapeutic or cosmeceutical use. Cryopreserved MSCs may be thawed in preparation for therapeutic and cosmeceutical use. MSCs express CD9, CD10, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, and HLA class I, and have low or no expression of CD3 and HLA class II.

Claims

1. A method for obtaining menstrual stem cells, the method comprising the steps of:

a) isolating menstrual stem cells from menstrual flow; and

b) processing the menstrual stem cells isolated from the menstrual flow.

2. The method of claim 1, wherein the step of isolating menstrual stem cell from the menstrual flow comprises processing the menstrual flow with at least one of centrifugation, density gradient centrifugation, filtration or sedimentation.

3. The method of claim 1, wherein the step of processing the menstrual stem cells isolated from the menstrual flow comprises selecting menstrual stem cells for at least one cell marker comprising CD9, CD10, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, and HLA class I.

4. The method of claim 3, wherein the step of processing the menstrual stem cells comprises the further step of culturing menstrual stem cells.

5. The method of claim 4, wherein the step of processing menstrual stem cells comprises the further step of selecting menstrual stem cells for at least one cell marker comprising CD9, CD10, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, and HLA class I.

6. The method of claim 5, wherein the step of processing menstrual stem cells comprises the further step of culturing menstrual stem cells.

7. The method of claim 1, wherein the step of processing menstrual stem cells isolated from the menstrual flow comprises culturing menstrual stem cells.

8. The method of claim 7, wherein the step of processing the menstrual stem cells comprising the further step of selecting menstrual stem cells.

9. The method of claim 8, wherein the step of processing menstrual stem cells comprises the further step of culturing menstrual stem cells.

10. The method of claim 9, wherein the step of processing menstrual stem cells comprises the further step of selecting menstrual stem cells for a cell marker.

11. The method of claim 1, wherein the method comprises the further step of cryopreserving menstrual stem cells.

12. The method of claim 11, wherein the method comprises the further steps of thawing cryopreserved menstrual stem cells and processing thawed menstrual stem cells.

13. The method of claim 1, wherein the method comprises the further step of preparing a therapeutic composition comprising menstrual stem cells and a cell media to maintain viability of the menstrual stem cells.

14. The method of claim 1, wherein the method comprises the further step of preparing a cosmeceutical composition comprising menstrual stem cells and a cosmeceutical preparation.

15. A process for collecting menstrual stem cells from menstrual flow, the process comprising:

a) procuring menstrual flow during a menstrual cycle;

b) transporting the menstrual flow to a processing facility;

c) isolating menstrual stem cells from menstrual flow into a cell preparation; and

d) processing the cell preparation of menstrual stem cells.

16. A system for collecting menstrual stem cells from menstrual flow, the system comprising:

a) a menstrual stem cell isolator, wherein menstrual stem cell isolator separates menstrual stem cells from menstrual flow;

b) a menstrual stem cell collector, wherein the menstrual stem cell collector collects the menstrual stem cells; and

c) a menstrual stem cell processor, wherein the menstrual stem cell processor prepares menstrual stem cells for therapeutic use or cryopreservation.

17. A method for cryopreserving menstrual stem cells, the method comprising the steps of:

a) isolating menstrual stem cells from menstrual flow collected during menstruation;

b) collecting menstrual stem cells isolated from menstrual flow; and

c) cryopreserving menstrual stem cells isolated from the menstrual flow.

18. The method of claim 17, wherein the step of isolating menstrual stem cells from the menstrual flow comprises processing the menstrual flow by at least one of centrifugation, density gradient centrifugation, filtration or sedimentation.

19. The method of claim 17, wherein the step of collecting menstrual stem cells isolated from menstrual flow comprises at least one step of selecting menstrual stem cells for a cell marker.

20. The method of claim 19, wherein the step of collecting menstrual stem cells isolated from menstrual flow comprises at least one step of culturing selected menstrual stem cells.

21. The method of claim 17, wherein the step of collecting menstrual stem cells isolated from menstrual flow comprises at least one step of culturing menstrual stem cells.

22. The method of claim 21, wherein the step of collecting menstrual stem cells isolated from menstrual flow comprises at least one step of selecting menstrual stem cells from a cell culture.

23. A population of menstrual stem cells obtained by the process comprising:

a) isolating menstrual stem cells from menstrual flow collected during menstruation; and

b) collecting menstrual stem cells isolated from menstrual flow.

24. A process for enriching a population of menstrual stem cells collected from menstrual flow, the process comprising the steps of:

a) isolating menstrual stem cells from menstrual flow collected during menstruation; and

b) collecting menstrual stem cells isolated from menstrual flow.

25. The process of claim 24, wherein the process comprises at least one step of selecting menstrual stem cells for at least one of a cell marker CD9, CD10, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, and HLA class I.

26. The process of claim 24, wherein the process comprises at least one step of culturing menstrual stem cells.

27. The process of claim 24, wherein the process comprises at least one step of selecting menstrual stem cells and at least one step of culturing selected menstrual stem cells.

28. The process of claim 24, wherein the process comprises at least one step of culturing menstrual stem cells and at least one step of selecting menstrual stem cells from a cell culture.

29. A process for enriching a population of menstrual stem cells expressing CD117, the process comprising the steps of:

a) isolating menstrual stem cells from menstrual flow,

b) collecting menstrual stem cells isolated from menstrual flow; and

c) selecting menstrual stem cells expressing CD117.

30. A population of menstrual stem cells comprising at least one of the cell markers comprising CD9, CD10, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, and HLA class I.

31. An enriched population of cells comprising menstrual stem cells

a) expressing at least one of the cell markers comprising CD9, CD10, CD13, CD29, CD44, CD49e, CD49f, CD59, CD81, CD105, CD166, and HLA class I;

and

b) expressing low or no of at least one of the cell markers comprising CD3 and HLA class II.

32. A composition comprising at least one menstrual stem cell and a cryopreservation agent.

33. A composition comprising at least one menstrual stem cell and a cell media.

34. A composition comprising at least one menstrual stem cell and a cosmeceutical agent.

35. A composition comprising at least one menstrual stem cell and a preservation agent to maintain cell viability.

36. A composition comprising at least one menstrual stem cell and cell media in a container in preparation for therapeutic use of the at least one menstrual stem cell.